Your session is about to expire
← Back to Search
Clinical Trial Match-List Intervention for Cancer Research Access (DISRUPT Trial)
N/A
Recruiting
Led By Nina Bickell
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months post intervention implementation
Awards & highlights
DISRUPT Trial Summary
This trial is designed to reduce cancer disparities in the United States by partnering with local organizations to increase awareness and demand for access to cancer research, creating an electronic system to match patients with trials, and providing training in diversity and social determinants of health to scientists.
Who is the study for?
This trial is for adults over 21 with invasive breast, prostate, or liver cancer who are facing a treatment decision. Participants must be able to consent and communicate in English or Spanish. Oncologists and related specialists caring for these patients can also join if they agree.Check my eligibility
What is being tested?
DISRUPT aims to improve diversity in clinical trials (CTs) by creating new community norms around cancer care, matching patients with CTs electronically at decision points, and integrating training on diversity into scientific research.See study design
What are the potential side effects?
Since this study focuses on improving clinical trial processes rather than testing drugs directly, it does not involve typical medication side effects. However, there may be indirect effects from changes in access to or participation in various treatments.
DISRUPT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 6 months post intervention implementation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months post intervention implementation
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Clinical Trial Accrual
Secondary outcome measures
Number of physicians agree to usefulness of the match lists
Patient Post-intervention Survey
Physician Post -intervention survey
DISRUPT Trial Design
2Treatment groups
Active Control
Group I: Patient ParticipantsActive Control1 Intervention
Patients with invasive breast, prostate or liver cancer, who face a treatment decision
Group II: Physician ParticipantsActive Control1 Intervention
Oncologists, and advanced practitioners caring for patients with breast, prostate, liver cancer including medical, surgical, radiation oncologists, interventional radiologists, urologists & hepatologists
Find a Location
Who is running the clinical trial?
Icahn School of Medicine at Mount SinaiLead Sponsor
860 Previous Clinical Trials
523,276 Total Patients Enrolled
11 Trials studying Breast Cancer
23,017 Patients Enrolled for Breast Cancer
Nina BickellPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are not in urgent need of medical treatment.I am over 21 and have breast, prostate, or liver cancer needing treatment decisions.I do not have invasive breast, prostate, or liver cancer.I cannot understand English or Spanish.I am unable to give consent by myself.I can give consent and speak English or Spanish.
Research Study Groups:
This trial has the following groups:- Group 1: Patient Participants
- Group 2: Physician Participants
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is recruitment open for this experiment at the moment?
"Clinicaltrials.gov confirms that this particular trial is not enrolling patients at the moment, despite having been initially posted on November 1st 2022 and updated most recently in the following month. However, 2410 other clinical trials are presently welcoming new candidates into their studies."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger